EGM
AKBA icon

Engineers Gate Manager’s Akebia Therapeutics AKBA Stock Holding History

Engineers Gate Manager’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-79,587
Closed -$111K – 2207
2026
Q1 		$111K Buy
+79,587
New +$109K ﹤0.01% 2005
2025
Q4 		– Sell
-46,345
Closed -$127K – 2066
2025
Q3 		$127K Buy
+46,345
New +$154K ﹤0.01% 1982
2022
Q1 		– Sell
-80,072
Closed -$181K – 1809
2021
Q4 		$181K Buy
+80,072
New +$218K 0.01% 1688
2021
Q1 		– Sell
-44,300
Closed -$124K – 1780
2020
Q4 		$124K Sell
44,300
-147,700
-77% -$431K 0.01% 1562
2020
Q3 		$482K Buy
+192,000
New +$1.68M 0.02% 1015

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Engineers Gate Manager's AKBA Position: Q2 2026 in Review

Engineers Gate Manager sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 79,587 shares — an estimated $111K sold.

Engineers Gate Manager first reported a position in AKBA in Q3 2020 and held it in 5 quarters. The position peaked at $482K in Q3 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Engineers Gate Manager reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Engineers Gate Manager sold 79,587 Akebia Therapeutics shares in Q2 2026, an estimated $111K.
  • Engineers Gate Manager first reported a position in Akebia Therapeutics in Q3 2020 and held it in 5 quarters.
  • Engineers Gate Manager's Akebia Therapeutics position peaked at $482K in Q3 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.